Detalles de la búsqueda
1.
Divergent clinical outcomes in a phase 2B trial of the TLPLDC vaccine in preventing melanoma recurrence and the impact of dendritic cell collection methodology: a randomized clinical trial.
Cancer Immunol Immunother;
72(3): 697-705, 2023 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-36045304
2.
Maximizing Benefit of Virtual Learning: Lessons From the Coronavirus Disease 2019 Pandemic.
J Surg Res;
275: 43-47, 2022 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-35219250
3.
Subgroup analysis of nelipepimut-S plus GM-CSF combined with trastuzumab versus trastuzumab alone to prevent recurrences in patients with high-risk, HER2 low-expressing breast cancer.
Clin Immunol;
225: 108679, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33485895
4.
Correlation of tumor microenvironment from biopsy and resection specimens in untreated colorectal cancer patients: a surprising lack of agreement.
Cancer Immunol Immunother;
70(5): 1465-1474, 2021 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-33180182
5.
A Phase IIb Randomized Controlled Trial of the TLPLDC Vaccine as Adjuvant Therapy After Surgical Resection of Stage III/IV Melanoma: A Primary Analysis.
Ann Surg Oncol;
28(11): 6126-6137, 2021 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-33641012
6.
An Educational Intervention Reduces Opioids Prescribed Following General Surgery Procedures.
J Surg Res;
257: 399-405, 2021 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32892137
7.
Prospective, randomized, single-blinded, multi-center phase II trial of two HER2 peptide vaccines, GP2 and AE37, in breast cancer patients to prevent recurrence.
Breast Cancer Res Treat;
181(2): 391-401, 2020 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-32323103
8.
Initial safety analysis of a randomized phase II trial of nelipepimut-Sâ¯+â¯GM-CSF and trastuzumab compared to trastuzumab alone to prevent recurrence in breast cancer patients with HER2 low-expressing tumors.
Clin Immunol;
201: 48-54, 2019 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-30817999
9.
Effects of HLA status and HER2 status on outcomes in breast cancer patients at risk for recurrence - Implications for vaccine trial design.
Clin Immunol;
195: 28-35, 2018 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-30025819
10.
Phase Ib trial of folate binding protein (FBP)-derived peptide vaccines, E39 and an attenuated version, E39': An analysis of safety and immune response.
Clin Immunol;
192: 6-13, 2018 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-29574039
11.
A phase I/IIa clinical trial in stage IV melanoma of an autologous tumor-dendritic cell fusion (dendritoma) vaccine with low dose interleukin-2.
Cancer Immunol Immunother;
65(4): 383-92, 2016 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-26894495
12.
Tumor infiltrating lymphocytes as an endpoint in cancer vaccine trials.
Front Immunol;
14: 1090533, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-36960052
13.
A practical guide to appendicitis evaluation and treatment.
J Fam Pract;
71(1): 11-17, 2022 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35259325
14.
Chemoprevention in familial adenomatous polyposis: past, present and future.
Fam Cancer;
20(1): 23-33, 2021 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32507936
15.
Safety and efficacy of autologous tumor lysate particle-loaded dendritic cell vaccination in combination with systemic therapies in patients with recurrent and metastatic melanoma.
Melanoma Res;
31(4): 378-388, 2021 08 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34193804
16.
Multi-institutional, prospective, randomized, double-blind, placebo-controlled phase IIb trial of the tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine to prevent recurrence in high-risk melanoma patients: A subgroup analysis.
Cancer Med;
10(13): 4302-4311, 2021 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-33982452
17.
Using Technology to Maintain the Education of Residents During the COVID-19 Pandemic.
J Surg Educ;
77(4): 729-732, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-32253133
18.
Final analysis of a phase I/IIa trial of the folate-binding protein-derived E39 peptide vaccine to prevent recurrence in ovarian and endometrial cancer patients.
Cancer Med;
8(10): 4678-4687, 2019 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-31274231
19.
Initial phase I/IIa trial results of an autologous tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine in patients with solid tumors.
Vaccine;
36(23): 3247-3253, 2018 05 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-29724512
20.
Tumor lysate particle loaded dendritic cell vaccine: preclinical testing of a novel personalized cancer vaccine.
Immunotherapy;
10(5): 373-382, 2018 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-29473470